These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16221742)

  • 1. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition.
    Davis BB; Morisseau C; Newman JW; Pedersen TL; Hammock BD; Weiss RH
    J Pharmacol Exp Ther; 2006 Feb; 316(2):815-21. PubMed ID: 16221742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation.
    Davis BB; Thompson DA; Howard LL; Morisseau C; Hammock BD; Weiss RH
    Proc Natl Acad Sci U S A; 2002 Feb; 99(4):2222-7. PubMed ID: 11842228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.
    Zhao X; Yamamoto T; Newman JW; Kim IH; Watanabe T; Hammock BD; Stewart J; Pollock JS; Pollock DM; Imig JD
    J Am Soc Nephrol; 2004 May; 15(5):1244-53. PubMed ID: 15100364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea.
    Watanabe T; Morisseau C; Newman JW; Hammock BD
    Drug Metab Dispos; 2003 Jul; 31(7):846-53. PubMed ID: 12814960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.
    Ng VY; Morisseau C; Falck JR; Hammock BD; Kroetz DL
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2462-8. PubMed ID: 16917105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors.
    Fang X; Hu S; Watanabe T; Weintraub NL; Snyder GD; Yao J; Liu Y; Shyy JY; Hammock BD; Spector AA
    J Pharmacol Exp Ther; 2005 Jul; 314(1):260-70. PubMed ID: 15798002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels.
    Olearczyk JJ; Field MB; Kim IH; Morisseau C; Hammock BD; Imig JD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1307-14. PubMed ID: 16772540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.
    Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S
    Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells.
    Kim HS; Kim SK; Kang KW
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels.
    Fang X; Weintraub NL; McCaw RB; Hu S; Harmon SD; Rice JB; Hammock BD; Spector AA
    Am J Physiol Heart Circ Physiol; 2004 Dec; 287(6):H2412-20. PubMed ID: 15284062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidyl-urea based inhibitors of soluble epoxide hydrolases.
    Morisseau C; Newman JW; Tsai HJ; Baecker PA; Hammock BD
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5439-44. PubMed ID: 16908134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.
    Tsai HJ; Hwang SH; Morisseau C; Yang J; Jones PD; Kasagami T; Kim IH; Hammock BD
    Eur J Pharm Sci; 2010 Jun; 40(3):222-38. PubMed ID: 20359531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs).
    Das N; Dhanawat M; Kulshrestha A; Shrivastava SK
    Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
    Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD
    J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors.
    Kundu B; Dvorácskó S; Basu A; Pommerolle L; Kim KA; Wood CM; Gibbs E; Behee M; Tarasova NI; Cinar R; Iyer MR
    Molecules; 2024 Jun; 29(13):. PubMed ID: 38998987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,3-Disubstituted and 1,3,3-trisubstituted adamantyl-ureas with isoxazole as soluble epoxide hydrolase inhibitors.
    Burmistrov V; Morisseau C; Danilov D; Harris TR; Dalinger I; Vatsadze I; Shkineva T; Butov GM; Hammock BD
    Bioorg Med Chem Lett; 2015 Dec; 25(23):5514-9. PubMed ID: 26520661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors.
    Imig JD
    Cardiovasc Drug Rev; 2006; 24(2):169-88. PubMed ID: 16961727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase.
    Manickam M; Pillaiyar T; Boggu P; Venkateswararao E; Jalani HB; Kim ND; Lee SK; Jeon JS; Kim SK; Jung SH
    Eur J Med Chem; 2016 Jul; 117():113-24. PubMed ID: 27092411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors.
    Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potent soluble epoxide hydrolase inhibitor, t-AUCB, modulates cholesterol balance and oxidized low density lipoprotein metabolism in adipocytes in vitro.
    Shen L; Peng H; Zhao S; Xu D
    Biol Chem; 2014 Apr; 395(4):443-51. PubMed ID: 24225128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.